Document is current

Article History

Received: 15 November 2021

Accepted: 13 March 2022

First Online: 24 March 2022

Declarations

:

: Not applicable.

: Not applicable.

: Z. Almassyzs, V. Christophidou-Anastasiadou, I. Barisic, R. Čerkauskienė, M Djordjevic, A. Hlavata, B. Kiec-Wilk, V. Plaiasu, M. Samardzic have no competing interests to declare. D. Avdjieva-Tzavella has received speaker honoraria, travel and accommodation funding from Takeda and Sanofi Genzyme. G. Cuturilo has received speaker honoraria and/or travel grants from BioMarin, Takeda and Sanofi Genzyme. Z. Gucev has received speaker and advisory board honoraria from Novo Nordisk, Merck, and Takeda. C. Lampe has received advisory board and speaker honoraria, travel expenses and consultancy honoraria from Sanofi, BioMarin, Amicus, Alexion, Takeda, Chiesi, Regenxbio. M. Magner has received speaker honoraria from BioMarin and Takeda and consultancy fees from BioMarin and Chiesi. I. Pecin has received advisory board and speaker honoraria from Sanofi, Sandoz, Genzyme, Takeda, Amicus. A. Tylki-Sziymanska has received speaker honoraria and/or travel grants from BioMarin, Sanofi Genzyme, Alexion, Chiesi, and Shire/Takeda. D. Zafeiriou has received honoraria, travel and research grants from Sanofi-Genzyme, Takeda, BioMarin, Novartis, Biogen and UCB. I. Zaganas has received consultancy honoraria from Akcea, Alnylam, BioMarin, Genesis Pharma, Roche, Specifar/Teva.